Mycophenolate use in dermatology: A clinical audit
Mycophenolate use in dermatology: A clinical audit
复制标题
霉酚酸酯在皮肤科的应用：临床审核
DOI：
--
复制
发表时间：
2013
影响因子：
2
通讯作者：
C. Baker
中科院分区：
文献类型：
--
作者：
Jane Li;A. Chong;Jack Green;R. Kelly;C. Baker
霉酚酸酯在皮肤科中的使用正在增长，因为它作为一种具有良好副作用的类固醇节省剂而闻名。然而，关于霉酚酸酯对许多皮肤病适应症的疗效和耐受性的数据有限。我们对2010年4月至2012年1月期间在我们机构接受麦考酚酯治疗的33名皮肤科患者进行了回顾性临床审计。最常见的适应症是坏疽性脓毒症（14例），其次是特应性皮炎（7例）。总体而言，70%的患者从麦考酚酯治疗中获益，12%的患者没有反应。45%的患者出现了副作用，其中两人出现了严重的副作用。女性似乎是不良反应的一个风险因素。我们的结论是，虽然霉酚酸酯是一个有前途的代理商在各种皮肤病的条件，需要进一步的随机对照试验。
Mycophenolate use in dermatology is growing due to its reputation as a steroid‐sparing agent with a favourable side‐effect profile. However, there are limited data on the efficacy and tolerability of mycophenolate for many dermatological indications. We conducted a retrospective clinical audit in 33 dermatology patients who had received mycophenolate at our institution between April 2010 and January 2012. The top indication was pyoderma gangrenosum (14 patients) followed by atopic dermatitis (seven patients). Overall 70 per cent of patients showed some benefit from mycophenolate treatment, with 12 per cent failing to respond. Side‐effects were experienced by 45 per cent of patients, two of whom had serious side‐effects. Female sex appears to be a risk factor for adverse effects. We conclude that although mycophenolate is a promising agent across a variety of dermatological conditions, further randomised controlled trials are required.